Steven Cohen Tg Therapeutics, Inc. Transaction History

Point72 Asset Management, L.P.

$36.6 Billion
Q3 2024

A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 100,000 shares of TGTX stock, worth $2.88 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

100,000

Previous 585,873 82.93%

Holding current value

$2.88 Million

Previous $10.4 Million 77.56%

% of portfolio

0.01%

Previous 0.03%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$13.32 - $19.19 $7.8 Million - $11.2 Million	585,873 New	585,873 $10.4 Million
Q3 2023 Nov 14, 2023	BUY	$8.36 - $26.5 $2.45 Million - $7.78 Million	293,408 Added 92.19%	611,678 $5.11 Million
Q2 2023 Aug 14, 2023	BUY	$15.48 - $35.0 $4.61 Million - $10.4 Million	297,589 Added 1438.95%	318,270 $7.91 Million
Q1 2023 May 15, 2023	BUY	$10.23 - $19.34 $211,566 - $399,970	20,681 New	20,681 $311,000
Q3 2022 Nov 14, 2022	BUY	$4.57 - $8.4 $2 Million - $3.67 Million	437,200 New	437,200 $2.59 Million
Q4 2019 Feb 14, 2020	SELL	$5.1 - $11.2 $101,209 - $222,264	-19,845 Closed	0 $0
Q3 2019 Nov 15, 2019	SELL	$5.38 - $8.99 $3.66 Million - $6.11 Million	-680,155 Reduced 97.17%	19,845 $111,000
Q2 2019 Aug 14, 2019	SELL	$6.27 - $8.65 $3.63 Million - $5.01 Million	-578,900 Reduced 45.27%	700,000 $6.06 Million
Q1 2019 May 15, 2019	BUY	$4.02 - $8.04 $5.14 Million - $10.3 Million	1,278,900 New	1,278,900 $10.3 Million
Q2 2018 Aug 14, 2018	SELL	$12.5 - $15.0 $7.55 Million - $9.06 Million	-603,800 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$8.7 - $16.8 $5.25 Million - $10.1 Million	603,800 New	603,800 $8.57 Million

Others Institutions Holding TGTX

# of Institutions

337

Shares Held

87.7M

Call Options Held

2.35M

Put Options Held

1.7M

View Full List

About TG THERAPEUTICS, INC.

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.18B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

More about TGTX

Track Steven Cohen's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.

Account